Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lethal Congenital Contracture Syndrome 2 × seribantumab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Lethal Congenital Contracture Syndrome 2 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

seribantumab 1 pembrolizumab 1 enzalutamide 1 Paroxetine 1 Itraconazole 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed

162 enrolled 11 charts

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡